--- title: "Pediatrix Medical | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 476.2 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285190389.md" datetime: "2026-05-05T10:52:10.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285190389.md) - [en](https://longbridge.com/en/news/285190389.md) - [zh-HK](https://longbridge.com/zh-HK/news/285190389.md) --- # Pediatrix Medical | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 476.2 M Revenue: As of FY2026 Q1, the actual value is USD 476.2 M, beating the estimate of USD 465.82 M. EPS: As of FY2026 Q1, the actual value is USD 0.36, beating the estimate of USD 0.3266. EBIT: As of FY2026 Q1, the actual value is USD 47.11 M. #### Net Revenue Pediatrix Medical Group, Inc. reported net revenue of $476.2 million for the three months ended March 31, 2026, an increase from $458.4 million in the prior-year period. This growth was primarily driven by a 2.8 percent increase in same-unit revenue and non-same unit activity from recent acquisitions, partially offset by practice dispositions. Same-unit revenue from net reimbursement-related factors increased by 4.4 percent, reflecting improved cash collections, higher hospital contract administrative fees, increased patient acuity, and a slightly favorable shift in payor mix. The percentage of services reimbursed by commercial and other non-government payors increased by 45 basis points compared to the prior-year period. #### Operational Metrics - **Net Income**: Net income for the first quarter of 2026 was $29.6 million, compared to $20.7 million for the first quarter of 2025. - **Adjusted EBITDA**: Adjusted EBITDA for the first quarter of 2026 was $58.2 million, an increase from $49.2 million in the prior-year period. - **Practice Salaries and Benefits**: These expenses were $345.7 million for the first quarter of 2026, up from $337.0 million in the prior-year period. - **General and Administrative Expenses**: These expenses amounted to $60.3 million for the first quarter of 2026, compared to $58.6 million in the prior-year period. - **Transformational and Restructuring Related Expenses**: These expenses decreased to $4.9 million for the first quarter of 2026, from $6.6 million in the prior-year period. - **Depreciation and Amortization Expense**: This was $6.1 million for the first quarter of 2026, compared to $5.3 million for the same period in 2025. - **Interest Expense**: Interest expense was $8.3 million for the first quarter of 2026, down from $9.2 million in the first quarter of 2025. - **Investment and Other Income**: This was $4.8 million for the first quarter of 2026, compared to $4.7 million for the prior-year period. #### Unique Operational Metrics - **Same-Unit Patient Volume**: Same-unit revenue attributable to patient volume decreased by 1.6 percent for the first quarter of 2026. Specific declines included hospital-based patient services by -1.5%, office-based patient services by -3.3%, and Neonatal Intensive Care Unit (NICU) days by -0.8%. #### Cash Flow and Financial Position - **Cash and Cash Equivalents**: Cash and cash equivalents stood at $205.8 million at March 31, 2026, down from $375.2 million at December 31, 2025. - **Net Accounts Receivable**: Net accounts receivable were $224.8 million at March 31, 2026. - **Cash Flow from Operations**: Pediatrix Medical Group, Inc. used - $129.5 million in cash to fund continuing operations for the first quarter of 2026, compared to - $116.1 million used in the first quarter of 2025. - **Other Cash Uses**: The company used $21.5 million for share repurchases, $7.0 million for acquisitions, and $6.2 million for capital expenditures during the first quarter of 2026. - **Total Debt**: Total debt outstanding was $591 million at March 31, 2026, comprising $400 million in 5.375% Senior Notes due 2030 and $191 million in borrowings under its Term A Loan. The company had no outstanding borrowings under its $450 million revolving line of credit. #### Outlook / Guidance Pediatrix Medical Group, Inc. reaffirms its full year 2026 outlook for Adjusted EBITDA. The company anticipates Adjusted EBITDA to be in a range of $280 million to $300 million for the year. ### Related Stocks - [MD.US](https://longbridge.com/en/quote/MD.US.md) ## Related News & Research - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [Advance Auto Parts Reports First Quarter 2026 Results; Reaffirms Full Year 2026 Guidance | AAP Stock News](https://longbridge.com/en/news/287202242.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [LOWE'S REPORTS FIRST QUARTER 2026 SALES AND EARNINGS RESULTS | LOW Stock News](https://longbridge.com/en/news/287043063.md) - [Yatra Online, Inc. to Host Fourth Quarter and Full Year 2026 Financial Results Call on May 25, 2026 | YTRA Stock News](https://longbridge.com/en/news/287242169.md)